Kumar Organic Products Limited
Letter data
- Company
- Kumar Organic Products Limited
- Recipient
- Mr. K. K. Singh | Chairman | Kumar Organic Products Limited | Plot No. 379 Canal Road | Maitri Marg, Village Luna, Taluka Padra District | Vadodara | 391440 | Gujarat | India
- Issue date
- 2023-07-24
- Posted date
- Not available
- FDA office
- Center for Drug Evaluation and Research | CDER
- Subject
- Not available
- Product
- Drugs
- CMS ID
- 598683
- Reference number
- Not available
- FEI
- 3009167769
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Kumar Organic Products Limited
MARCS-CMS 598683 —
July 24, 2023
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Reference #:
FEI 3009167769
Product:
Drugs
Recipient:
Recipient Name
Mr. K. K. Singh
Recipient Title
Chairman
Kumar Organic Products Limited
Plot No. 379 Canal Road
Maitri Marg, Village Luna, Taluka Padra District
Vadodara
391440
Gujarat
India
Issuing Office:
Center for Drug Evaluation and Research | CDER
United States
Dear Mr. Singh:
The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-20-34 dated April 23, 2020.
Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.
The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations and/or deviations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Michael Klapal
Compliance Officer
Division of Drug Quality II
Office of Manufacturing Quality
Office of Compliance
Center for Drug Evaluation and Research
Content current as of:
07/27/2023
Regulated Product(s)
Drugs